[An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants].

Sánchez Luna, ManuelPérez Muñuzuri, AlejandroLeante Castellanos, José LuisRuiz Campillo, César WSanz López, EsterBenavente Fernández, IsabelSánchez Redondo, María DoloresRite Gracia, Segundoen representación de la Comisión de Estándares de la Sociedad Española de Neonatología2023-01-252023-01-252019-10-01http://hdl.handle.net/10668/14586esAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Antiviral AgentsDrug Administration ScheduleHumansInfant, NewbornInfant, PrematureInfant, Premature, DiseasesNeonatologyPalivizumabPractice Guidelines as TopicRespiratory Syncytial Virus InfectionsRiskSocieties, MedicalSpain[An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants].Recomendaciones de la Sociedad Española de Neonatología para la utilización de palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial en lactantes de alto riesgo, actualización.research article31585838open access10.1016/j.anpedi.2019.08.0032341-2879https://doi.org/10.1016/j.anpedi.2019.08.003